Morphosys AG (MORG.DE)

MORG.DE on Xetra

23 Dec 2014
Price Change (% chg)

€-0.83 (-1.08%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for MORG.DE


Morphosys AG is a German biotechnology company focused on generation of fully human antibodies. It operates two business segments: Partnered Discovery and Proprietary Development. The Partnered Discovery business segment comprises technologies for the generation of human antibody therapeutics, which is exploited via partnerships... (more)


Beta: 0.35
Market Cap (Mil.): €2,017.16
Shares Outstanding (Mil.): 26.44
Dividend: --
Yield (%): --


  MORG.DE Industry Sector
P/E (TTM): -- 149.43 38.63
EPS (TTM): -0.22 -- --
ROI: -1.36 -0.54 18.26
ROE: -1.58 -1.67 19.13
Search Stocks

Morphosys gets payment from Novartis for oncology research

FRANKFURT, Dec 22 - Morphosys AG on Monday said it had received a payment from Novartis in connection with the initiation of a phase 1 clinical trial of a HuCAL antibody in the field of oncology.

22 Dec 2014

UPDATE 3-Double blow for Roche as breast cancer, Alzheimer's studies fail

* Breast cancer study fails to prove added Kadcyla benefit

19 Dec 2014

BRIEF-Morphosys gets positive EMA opinion on MOR208 orphan status

* Says mor208 program receives positive opinion for orphan medicinal product designation from EMA for DLBCL

15 Dec 2014

BRIEF-Morphosys announces data from Phase 2a study of MOR208

* Announced promising clinical data on its proprietary drug candidate mor208 from a phase 2a study

08 Dec 2014

Morphosys raises forecasts on Janssen Biotech milestone payment

FRANKFURT, Oct 23 - German biotech company Morphosys raised its earnings forecast for 2014, citing a milestone payment from Janssen Biotech as well as a partial shift of development costs to 2015.

23 Oct 2014

BRIEF-Morphosys acquires Lanthipeptide Technology

* Says acquires Lanthipeptide Technology from Lanthio Pharma Source text for Eikon: Further company coverage:

15 Oct 2014

BRIEF-Morphosys shares rise after Q2 results

July 28 - Shares in Morphosys AG rise 2.6 percent at open after Q2 results

28 Jul 2014

BRIEF-Morphosys affirms outlook after Q2 loss

July 28 - Morphosys AG : * Says H1 revenues from continuing operations were EUR 30.5 million (H1 2013:

28 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Directors Deals Ltd.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
Provider: Thomson Reuters StreetEvents

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks